tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 26;10(10):1609.
doi: 10.3390/vaccines10101609.
Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022
Jeadran Malagón-Rojas[SUP] 1 [/SUP], Marcela Mercado-Reyes[SUP] 1 [/SUP], Yesith G Toloza-Pérez[SUP] 1 [/SUP], Marisol Galindo[SUP] 1 [/SUP], Ruth M Palma[SUP] 1 [/SUP], Jenssy Catama[SUP] 1 [/SUP], Juan F Bedoya[SUP] 1 [/SUP], Eliana L Parra-Barrera[SUP] 1 [/SUP], Ximena Meneses[SUP] 1 [/SUP], Juliana Barbosa[SUP] 1 [/SUP], Pilar Tavera-Rodríguez[SUP] 1 [/SUP], Andrea Bermúdez-Forero[SUP] 1 [/SUP], Martha Lucía Ospina-Martínez[SUP] 1 2 [/SUP]
Affiliations
Abstract
To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.
Keywords: COVID-19; Colombia; SARS-CoV-2; cohort; vaccine.
. 2022 Sep 26;10(10):1609.
doi: 10.3390/vaccines10101609.
Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022
Jeadran Malagón-Rojas[SUP] 1 [/SUP], Marcela Mercado-Reyes[SUP] 1 [/SUP], Yesith G Toloza-Pérez[SUP] 1 [/SUP], Marisol Galindo[SUP] 1 [/SUP], Ruth M Palma[SUP] 1 [/SUP], Jenssy Catama[SUP] 1 [/SUP], Juan F Bedoya[SUP] 1 [/SUP], Eliana L Parra-Barrera[SUP] 1 [/SUP], Ximena Meneses[SUP] 1 [/SUP], Juliana Barbosa[SUP] 1 [/SUP], Pilar Tavera-Rodríguez[SUP] 1 [/SUP], Andrea Bermúdez-Forero[SUP] 1 [/SUP], Martha Lucía Ospina-Martínez[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36298474
- DOI: 10.3390/vaccines10101609
Abstract
To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.
Keywords: COVID-19; Colombia; SARS-CoV-2; cohort; vaccine.